The appeal hearing for Amarin’s (AMRN) high triglyceride treatment Vascepa kicked off on Wednesday and ended on a negative note. The appeals court affirmed the district court’s ruling invalidating Vascepa’s patents in the US. Accordingly, shares took a merciless 37% plunge over the past two trading days.As a reminder, in March, Amarin lost a patent court case against generic drug makers, Hikma Pharmaceuticals and Dr. Reddy’s, which are seeking to sell their own versions of Vascepa.At the hearing’s conclusion, Stifel analyst Derek Archila bluntly stated, “We would not be buying shares here.”The analyst further said, “Given Vascepa’s complexity, we think …read more
Source:: Yahoo Finance
